MedPath

Does Improving Vagal Tone Increase Mitochondrial Bioenergetics

Not Applicable
Completed
Conditions
Functional Gastrointestinal Disorders
Dyspepsia
Functional Abdominal Pain Syndrome
Irritable Bowel Syndrome
Interventions
Device: Percutaneous neurostimulation
Registration Number
NCT03931330
Lead Sponsor
Medical College of Wisconsin
Brief Summary

This study evaluates the effect of auricular neurostimulation on mitochondrial bioenergetics and inflammation through vagal nerve modulation via non-invasive percutaneous electrical nerve field stimulator in children with functional gastrointestinal disorders.

Detailed Description

In understanding the pathophysiology of pediatric functional gastrointestinal disorders (FGID), it has been documented that subjects have decreased vagal tone. Vagal tone in turn modulates mitochondrial bioenergetics and plays a role in anti inflammatory effects. Further defining these brain-body connections that underlie FGID's could help guide future treatment.

The investigators postulate that a 4 week neuro-stimulation with an Electro Auricular Device that has already shown to increase vagal tone will produce an increase in mitochondrial bioenergetics and decrease in inflammatory markers in this patient group.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
8
Inclusion Criteria
  • English-speaking and able to verbalize their condition and concerns about nausea, pain and other symptoms
  • Subjects will meet Rome IV criteria for functional nausea, irritable bowel syndrome, dyspepsia or functional abdominal pain as determined by a pediatric gastroenterologist
  • Patients must have an intact external ear that is free of infection or severe dermatological conditions, have stable vital signs for their respective age, no history of seizures and no currently implanted electrical device
Exclusion Criteria
  • Mental retardation or pervasive developmental disorder or epilepsy
  • Psychosis
  • Genetic or chromosomal disorders
  • Pregnancy
  • Subjects who admit to substance abuse during screening
  • Patients with findings of peptic ulcer disease, H.pylori gastritis, celiac disease, inflammatory bowel disease, allergic disorders, or any chronic condition or medication that may cause nausea or pain
  • Patients who are treated with opioids or who had any changes in their medical regimen in the past four weeks prior to study
  • Patients with a history of allergy to adhesives

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Percutaneous neurostimulationPercutaneous neurostimulationSubjects will have 4 weeks of active therapy.
Primary Outcome Measures
NameTimeMethod
To Measure Different Mitochondrial Bioenergetic Markers, Including Basal Respiratory CapacityBaseline, at follow-up visit 4 (Week 4) and at follow up visit 5 (Week 8 or 12)

Blood draw will be tested for mitochondrial function, including basal respiratory capacity, ATP production and spare respiration and to detect changes in protein which can be an indicator for inflammation. Basal Respiratory Capacity (pmol/min) is better when value is higher.

Secondary Outcome Measures
NameTimeMethod
To Measure Heart Rate VariabilityAt date of baseline assessment (beginning of therapy). Also assessed at follow-up visit 4 (Week 4) and 5 (Week 8 or 12)

EKG tracing will be used to analyze Heart Rate Variability as an indirect measure of vagal nerve output and central autonomic control.

To Measure Functional Disability InventoryAt date of baseline assessment (beginning of therapy). Also assessed at follow-up visit 4 (Week 4) and visit 5 (8 or 12)

The Functional Disability Inventory (FDI) questionnaire will be used to assess change in symptoms. Participants will rank physical trouble or difficulty completing 15 different daily activities (Eating regular meals, Being at school all day, Walking up stairs, etc.) on a scale of 0-4.

Scale:0-No trouble

1. A little trouble

2. Some Trouble

3. A lot of Trouble

4. Impossible

Higher scores (4) indicate more difficulty functioning due to physical health. The total score ranges from 0 to 60 among 15 questions. The individual score for all 15 questions are added together for the total score. If all 15 questions are answered as 0- no trouble then the total score would be 0 (lowest difficulty). If all 15 questions are answered as 4-Impossible, then the total score would be 60 (highest difficulty). An assortment of answers will fall within this 0-60 range depending on the difficulty level answer for each question.

Trial Locations

Locations (1)

Medical College of Wisconsin

🇺🇸

Milwaukee, Wisconsin, United States

© Copyright 2025. All Rights Reserved by MedPath